|Updates from the National Cancer Institute|
|Clinical Trials News|
|Food and Drug Administration (FDA) Approves New Use for Lenlidomide in Multiple Myeloma|
The new approval for lenalidomide was based on two randomized double-blind trials that showed significantly longer progression-free survival in certain patients with multiple myeloma.
|Blinatumomab Extends Survival for Patients with Advanced Acute Lymphoblastic Leukemia (ALL)|
Results from a phase III randomized controlled trial show that patients with advanced ALL who received an immunotherapy drug called blinatumomab (Blincyto®) lived longer than patients who received standard chemotherapy regimens.
|Find NCI-Supported Clinical Trials|
Use our search form to find a clinical trial or other research study that may be right for you or a loved one.
|Clinical Trials Information for Patients and Caregivers|
|Deciding to Take Part in a Clinical Trial|
There are many things to think about when deciding to take part in a clinical trial. Learning about the potential benefits and risks can help patients make a decision that is right for them.
|Questions to Ask about Treatment Clinical Trials|
The questions on this pager can help patients gather information about a specific trial and help them decide if they want to join.
|NCI-Supported Clinical Trials that Are Recruiting Patients|
|Immunotherapy for Some Patients with Treatment-Resistant Lymphoma|
This phase I trial is for patients with CD30 positive lymphomas. It is studying the side effects and best dose of CD30 CAR-expressing autologous T lymphocytes.
|Reproductive Health Program in Women with Cancer|
This randomized trial is studying a reproductive health program in premenopausal women with cancer. A reproductive health program may improve patients’ understanding of reproductive risks and receipt of appropriate treatment to achieve their reproductive health goals.
|Olaparib Alone or with Cediranib versus Standard Chemotherapy|
This randomized phase II/III study is for women with certain high grade ovarian, fallopian tube, or primary peritoneal cancers that initially disappeared after platinum-based therapy but have come back. The purpose is to learn if giving cediranib and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy in women with platinum-resistant or platinum-refractory cancer.
BMC Medical Genetics | Home page
Hace 17 horas